Irish Journal of Medical Science

, Volume 179, Issue 4, pp 507–510

Incidence and significance of FLT3-ITD and NPM1 mutations in patients with normal karyotype acute myeloid leukaemia

  • K. Haslam
  • N. Chadwick
  • J. Kelly
  • P. Browne
  • E. Vandenberghe
  • C. Flynn
  • E. Conneally
  • S. E. Langabeer
Original Article

Abstract

Background

Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haematopoietic progenitor cells. Approximately half of all adult AML patients have a normal karyotype (NK-AML) and an intermediate risk prognosis.

Aims

To determine the incidence and prognostic significance of NPM1 and FLT3-ITD mutations in a population of patients with NK-AML.

Methods

FLT3-ITD and NPM1 mutation status was retrospectively sought in presentation samples from 44 NK-AML patients.

Results

FLT3-ITD and NPM1 mutations were detected in 45.5 and 54.5% of patients, respectively, allowing stratification according to genotype.

Conclusions

FLT3-ITD and NPM1 mutation status can be defined in NK-AML. Prospective screening for these mutations is advocated in all NK-AML patients, as the genotype is of clinical importance when considering treatment options including stem cell transplantation.

Keywords

AML Nucleophosmin FLT3-ITD Normal karyotype Prognosis Genotype 

References

  1. 1.
    Swerdlow SH, Campo E, Harris NL (eds) (2008) World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, LyonGoogle Scholar
  2. 2.
    Estey E, Dohner H (2006) Acute myeloid leukaemia. Lancet 368:1894–1907CrossRefPubMedGoogle Scholar
  3. 3.
    Grimwade D, Walker H, Oliver F et al (1998) The importance of diagnostics cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. Blood 92:2322–2333PubMedGoogle Scholar
  4. 4.
    Grimwade D, Hills RK, Moorman AV et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK MRC trials. Blood 116:354–365Google Scholar
  5. 5.
    Baldus CD, Mrozek K, Marcucci G, Bloomfield CD (2007) Clinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations. Br J Haematol 137:387–400CrossRefPubMedGoogle Scholar
  6. 6.
    Bacher U, Schnittger S, Haferlach C, Haferlach T (2009) Molecular diagnostics in acute leukemias. Clin Chem Lab Med 47:1333–1341CrossRefPubMedGoogle Scholar
  7. 7.
    Stirewalt DL, Radich JP (2003) The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3:650–665CrossRefPubMedGoogle Scholar
  8. 8.
    Kiyoi H, Naoe T, Nakano Y et al (1999) Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93:3074–3080PubMedGoogle Scholar
  9. 9.
    Kottaridis P, Gale RE, Frew ME et al (2001) The presence of a FLT-3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the UK MRC AML 10 and 12 trials. Blood 98:1752–1759CrossRefPubMedGoogle Scholar
  10. 10.
    Schnittger S, Schoch C, Dugas M et al (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detction of minimal residual disease. Blood 100:59–66CrossRefPubMedGoogle Scholar
  11. 11.
    Frohling S, Schlenk RF, Breitruck J et al (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100:4372–4380CrossRefPubMedGoogle Scholar
  12. 12.
    Falini B, Nicoletti I, Martelli MF, Mecucci C (2007) Acute myeloid leukemia carrying cyttoplasmic/mutated nucleophosmin (NPMc + AML): biologic and clinical features. Blood 109:874–885CrossRefPubMedGoogle Scholar
  13. 13.
    Falini B, Mecucci C, Tiacci E et al (2005) Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254–266CrossRefPubMedGoogle Scholar
  14. 14.
    Schnittger S, Schoch C, Kern W et al (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106:3733–3739CrossRefPubMedGoogle Scholar
  15. 15.
    Thiede C, Koch S, Creutzig E et al (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107:4011–4020CrossRefPubMedGoogle Scholar
  16. 16.
    Dohner K, Schlenk RF, Habdank M et al (2006) Mutant nucleophosmin (NPM1) predicts favourable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106:3740–3746CrossRefGoogle Scholar
  17. 17.
    Gale RE, Green C, Allen C et al (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111:2776–2784CrossRefPubMedGoogle Scholar
  18. 18.
    Schlenk RF, Dohner K, Krauter J et al (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909–1918CrossRefPubMedGoogle Scholar
  19. 19.
    Szankasi P, Jama M, Bahler DW (2008) A new DNA-based test for the detection of nucleophosmin exon 12 mutations by capillary electrophoresis. J Mol Diagn 10:236–241CrossRefPubMedGoogle Scholar
  20. 20.
    Schneider F, Hoster E, Unterhalt M et al (2009) NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS). Blood 113:5250–5253CrossRefPubMedGoogle Scholar
  21. 21.
    Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD (2007) Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 109:431–438CrossRefPubMedGoogle Scholar
  22. 22.
    Dohner H, Estey EH, Amadori S et al (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European leukemiaNet. Blood 115:453–474CrossRefPubMedGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2010

Authors and Affiliations

  • K. Haslam
    • 1
  • N. Chadwick
    • 2
  • J. Kelly
    • 3
  • P. Browne
    • 2
  • E. Vandenberghe
    • 2
  • C. Flynn
    • 2
  • E. Conneally
    • 2
  • S. E. Langabeer
    • 1
  1. 1.Cancer Molecular Diagnostics, Central Pathology LaboratorySt. James HospitalDublinIreland
  2. 2.Department of HaematologySt. James HospitalDublinIreland
  3. 3.National Centre for Medical GeneticsOur Lady’s Children’s HospitalDublinIreland

Personalised recommendations